ABSTRACT

Over the past 10 years, substantial progress has been made in the development of cell-penetrating peptide-based drug delivery systems. This was directly correlated with the dramatic acceleration in the production of new therapeutic molecules because the cell delivery systems described until then were restricted by very specific issues. As such, the goal became to design short synthetic peptides which would incorporate cellular addresses and intramolecular routing signals and to formulate synthetic peptide cargo complexes which could overcome both extracellular and intracellular limitations.